Currently, a dual CXCR1/2 inhibitor, SX-682, is being evaluated in combination with LAG-3 blockade and CD137 agonists or in combination with PD1 blockade in the context of surgically resectable cancer [273]. The gene discussed is LAG3; the disease is cancer.